These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 3545453

  • 1. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
    Ratliff TL, Palmer JO, McGarr JA, Brown EJ.
    Cancer Res; 1987 Apr 01; 47(7):1762-6. PubMed ID: 3545453
    [Abstract] [Full Text] [Related]

  • 2. Modulation of fibronectin-mediated Bacillus Calmette-Guérin attachment to murine bladder mucosa by drugs influencing the coagulation pathways.
    Hudson MA, Brown EJ, Ritchey JK, Ratliff TL.
    Cancer Res; 1991 Jul 15; 51(14):3726-32. PubMed ID: 2065329
    [Abstract] [Full Text] [Related]

  • 3. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response.
    Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL.
    J Clin Invest; 1990 Jan 15; 85(1):62-7. PubMed ID: 2404029
    [Abstract] [Full Text] [Related]

  • 4. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
    Zlotta AR, Drowart A, Van Vooren JP, de Cock M, Pirson M, Palfliet K, Jurion F, Vanonckelen A, Simon J, Schulman CC, Huygen K.
    J Urol; 1997 Feb 15; 157(2):492-8. PubMed ID: 8996341
    [Abstract] [Full Text] [Related]

  • 5. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity.
    Shapiro A, Ratliff TL, Oakley DM, Catalona WJ.
    Cancer Res; 1983 Apr 15; 43(4):1611-5. PubMed ID: 6339040
    [Abstract] [Full Text] [Related]

  • 6. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer.
    Ratliff TL, Kavoussi LR, Catalona WJ.
    J Urol; 1988 Feb 15; 139(2):410-4. PubMed ID: 3276931
    [Abstract] [Full Text] [Related]

  • 7. Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer.
    Zlotta A, Drowart A, van Vooren JP, Simon J, Schulman CC, Huygen K.
    Acta Urol Belg; 1994 Sep 15; 62(3):63-8. PubMed ID: 7976857
    [Abstract] [Full Text] [Related]

  • 8. [Enhancement of bacillus Calmette-Guerin attachment to the bladder wall: experimental study].
    Shen Z, Ding G, Chen Z.
    Zhonghua Wai Ke Za Zhi; 2001 Dec 15; 39(12):951-3. PubMed ID: 16201181
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y, Sawada Y, Inagaki T, Kohjimoto Y, Uekado Y, Shinka T.
    Int J Urol; 2007 Feb 15; 14(2):140-6. PubMed ID: 17302571
    [Abstract] [Full Text] [Related]

  • 11. Technical factors affecting the reproducibility of intravesical mouse bladder tumor implantation during therapy with Bacillus Calmette-Guérin.
    Shapiro A, Kelley DR, Oakley DM, Catalona WJ, Ratliff TL.
    Cancer Res; 1984 Jul 15; 44(7):3051-4. PubMed ID: 6373001
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the fibronectin-binding ability and antitumor efficacy of various mycobacteria.
    Hudson MA, Ritchey JK, Catalona WJ, Brown EJ, Ratliff TL.
    Cancer Res; 1990 Jul 01; 50(13):3843-7. PubMed ID: 2191767
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Study on enhancement of fibronectin-mediated bacillus Calmette-Guérin attachment to urinary bladder wall in rabbits.
    Shen ZJ, Wang Y, Ding GQ, Pan CW, Zheng RM.
    World J Urol; 2007 Oct 01; 25(5):525-9. PubMed ID: 17665201
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.
    Suttmann H, Riemensberger J, Bentien G, Schmaltz D, Stöckle M, Jocham D, Böhle A, Brandau S.
    Cancer Res; 2006 Aug 15; 66(16):8250-7. PubMed ID: 16912205
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.